Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas. - Wikidata - awgldk - TriplyDB

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

http://www.wikidata.org/entity/Q33683537

about

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

P2860

Q47140492-BC6B4595-75BC-4B83-A6D5-0A8095B3BCB7 Q54960825-7A2DD371-7484-494D-93AA-E1A51A5C8CE7

P2860

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

http://www.wikidata.org/entity/Q33683537

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

@ast

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

@en

type

label

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

@ast

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

@en

prefLabel

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

@ast

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

@en

P1433

Q33683537-2795A0F7-F863-4CAC-A738-C42B70C311A7

P1476

Q33683537-6DA356B6-56D1-4E52-B507-22747B8CB92D

P2093

Q33683537-7DC79AA1-19AD-4809-961A-745D5A90C12F

Q33683537-8614F42C-3F99-4244-963B-A9EFC494ECED

Q33683537-8AB46175-CEA8-4720-8B25-46D34F04E6F6

Q33683537-93B9D8E9-395E-4E63-9062-7B3863951F00

Q33683537-AF5ED5F6-C681-43BB-A603-103E7B48192F

Q33683537-EF5C026A-B0DF-4021-9D48-C7B30DD9DDEE

P2860

Q33683537-0263A087-4553-4D4E-8B5D-DC8925DBBCA5

Q33683537-03EC059D-598B-40CE-AE5C-C2B26023555D

Q33683537-0B43D1C0-79F0-4F92-B1D7-99B8CC0A7233

Q33683537-0DE6FE85-A5AF-474E-9961-F8255EA6EB13

Q33683537-1345FE57-9AB3-422C-97DC-9BA05049C6C4

Q33683537-15731E05-944F-4D84-97C9-4568B938EA70

Q33683537-16C8D862-7917-4DCC-8A8D-5F17E04BCDFC

Q33683537-18DC7E99-1CA0-4EEF-A30E-D19387C8386F

Q33683537-1A1F38C0-4ED6-4CE2-9E9B-91B4B46614B4

Q33683537-1B5A6CD4-6A23-450C-8409-853F34685AAE

P2888

Q33683537-A34D3790-8DED-4477-9FAD-FC46B0BD023B

P304

Q33683537-7995E102-D10A-4FA2-ADCC-CDFEC5993086

P31

Q33683537-B2082F8A-9B3F-41FA-81A3-1E080E15B0B4

P356

Q33683537-527B9D11-5E7B-461C-B20F-87B022E4124A

P407

Q33683537-54B71480-0FA7-4D65-906E-65C75F23AB13

P433

Q33683537-684320C9-5D4A-4AAD-BF2F-1FB87231C42A

P478

Q33683537-987DAAC1-D144-4DF3-83DC-C6E8DFC51627

P50

Q33683537-627E75B6-28FD-4F4E-A288-087180F6AD8D

Q33683537-7AAEB75F-955E-4036-B8F8-6EC74149DD5F

Q33683537-8267EF5C-F6F3-47D2-AB8D-D631F8FAE74F

Q33683537-895BF942-2BC0-4835-B0F4-B480EC18DE2B

Q33683537-9F42EC95-FB49-4DC2-BC46-1EC605603812

Q33683537-AF851D91-7B3C-48F8-9910-32DC5ED333CC

Q33683537-E5715AFB-3DE7-40D1-ABD0-6C14765A6E02

Q33683537-EA42B3D8-08C2-41B1-BE39-8514F9414B9D

P577

Q33683537-8E06833F-1177-4596-A96D-052513BDC69A

P6179

Q33683537-346DB49D-7AD3-4D76-8786-4567A9B1E65D

P698

Q33683537-1A95173E-9AB1-44CF-B54D-72902197C305

P932

Q33683537-8C506EA8-8A3E-4896-9140-2A536A128C99

P356

S41598-017-01425-9

P1433

Scientific Reports

P1476

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas

@en

P2093

Claudio Arra

http://www.w3.org/2001/XMLSchema#string

Gerardo Botti

http://www.w3.org/2001/XMLSchema#string

Giovanni Botti

http://www.w3.org/2001/XMLSchema#string

Katia Bifulco

http://www.w3.org/2001/XMLSchema#string

Maria Letizia Motti

http://www.w3.org/2001/XMLSchema#string

Susan Costantini

http://www.w3.org/2001/XMLSchema#string

P2860

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family

T Cell Migration in Rheumatoid Arthritis

Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion

Crystal structure of the urokinase receptor in a ligand-free form

Satisfying hydrogen bonding potential in proteins

GROMACS: fast, flexible, and free

The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation

Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer

Formyl-peptide receptors revisited

Biological role of the N-formyl peptide receptors

P2888

s41598-017-01425-9

P304

1312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-01425-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Gennaro Ciliberto

Giosuè Scognamiglio

Concetta Ragone

Maria Vincenza Carriero

Vincenzo Ingangi

Michele Minopoli

Antonello Pessi

P577

2017-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085107886

http://www.w3.org/2001/XMLSchema#string

P698

28465589

http://www.w3.org/2001/XMLSchema#string

P932

5430962

http://www.w3.org/2001/XMLSchema#string